Article(id=1326651907667505525, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651836028793729, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.11.014, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1742745600000, receivedDateStr=2025-03-24, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228062787, onlineDateStr=2026-11-09, pubDate=1762704000000, pubDateStr=2025-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228062787, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228062787, creator=13701087609, updateTime=1794228062787, updator=13701087609, issue=Issue{id=1326651836028793729, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='11', pageStart='1091', pageEnd='1200', issueExtLink='null', onlineDate='null', pubDate='1762704000000', pubDateStr='2025-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228045707, creator='13701087609', updateTime=1794272830165, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326839676083745583, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651836028793729, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326839676083745584, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651836028793729, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1181, endPage=1187, ext={EN=ArticleExt(id=1326651907889803638, articleId=1326651907667505525, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

In 2022, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association jointly released a clinical practice guideline that introduced the term progressive pulmonary fibrosis (PPF) to collectively refer to the progressive fibrotic phenotypes of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). These diseases may exhibit clinical course characteristics and core mechanisms of fibrosis similar to those of IPF, even after standardized treatment. Currently, the two anti-fibrotic drugs nintedanib and pirfenidone approved by the U.S. Food and Drug Administration, can only slow the decline in lung function in patients with IPF, but cannot reverse fibrosis. Due to the significant heterogeneity of PPF patient population and complex enrollment criteria, clinical trials targeting PPF often terminate due to recruitment challenges. Consequently, current drug development strategies primarily select IPF as the initial indication and then gradually expand to other fibrotic lung diseases after confirming effectiveness. In the research and development pipeline, most candidate drugs remain in the early stages of clinical development, with only a few advancing to phase Ⅱ/Ⅲ clinical studies and simultaneously exploring the PPF indication. Notably, in 2024, the world's first anti-fibrotic drug designed entirely using artificial intelligence (AI), INS018-055, successfully progressed to Phase Ⅱ clinical trials, marking a significant breakthrough application of AI technology in drug development. This article systematically dissected the conceptual framework of PPF, covering its definition, disease spectrum, epidemiological characteristics, and molecular mechanisms, while reviewed the latest clinical research advancements from the perspective of anti-fibrotic treatment, aiming to provide a theoretical foundation for the discovery of new targets and translational research.

, authors=Yanyan ZENG1, Siqian PENG1, Yan ZHENG2, Qihang YU2, Na NI1, *, Junlong Wang1, *, authorsList=Yanyan ZENG, Siqian PENG, Yan ZHENG, Qihang YU, Na NI, Junlong Wang, authorCompany=null, correspAuthors=Na NI, Junlong Wang, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326651908141461879, articleId=1326651907667505525, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=进展性肺纤维化抗纤维化治疗的临床研究新进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

2022年美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布的临床实践指南首次提出进展性肺纤维化(progressive pulmonary fibrosis,PPF)这一术语,用于统称除特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)外的其他类型间质性肺疾病进行性纤维化表型。此类疾病即使经过规范化治疗,仍可能呈现与IPF相似的临床病程特征及纤维化核心机制。目前,美国食品药品监督管理局批准的2种抗纤维化药物尼达尼布及吡非尼酮,仅能减缓IPF患者的肺功能下降,无法逆转纤维化。由于PPF患者群体异质性强、入组标准复杂,针对PPF的临床试验常因招募困难而终止。当前药物研发策略多选择以IPF为初始适应证,待验证有效性后逐步拓展至其他肺纤维化疾病。在研发管线中,多数候选药物尚处于临床早期阶段,仅少数进入Ⅱ/Ⅲ期临床试验并同步探索PPF适应证。值得注意的是,2024年全球首款基于纯人工智能设计的抗纤维化药物INS018-055已成功推进至Ⅱ期临床试验,标志着人工智能技术在药物开发中的突破性应用。该文系统解析PPF的概念框架,涵盖其定义、疾病谱系、流行病学特征及分子机制,并基于抗纤维化治疗视角综述最新临床研究进展,旨在为新型靶点发现及转化研究提供理论依据。

, authors=曾艳艳1, 彭思芊1, 郑岩2, 于启航2, 倪娜1, *, 王俊龙1, *, authorsList=曾艳艳, 彭思芊, 郑岩, 于启航, 倪娜, 王俊龙, authorCompany=null, correspAuthors=倪娜, 王俊龙, authorNote=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, correspAuthorsNote=
倪娜,副研究员,研究方向:创新药物的临床研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=FV+AHJWcE9GMFxSeh7nZ6Q==, magXml=QjBRHmp0EoHD6YjfVbgRRw==, pdfUrl=null, pdf=LfipV42503QdlZOnEUDAMg==, pdfFileSize=953221, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=QGVPGne9kpwTt5lO7U4SyA==, mapNumber=null, fund=null)}, authors=[Author(id=1326651908598641023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651908678332801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908598641023, language=EN, stringName=Yanyan ZENG, firstName=Yanyan, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651908762218882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908598641023, language=CN, stringName=曾艳艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

"}, bioImg=null, bioContent=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651908841910661, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651908955156871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908841910661, language=EN, stringName=Siqian PENG, firstName=Siqian, middleName=null, lastName=PENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651909039042952, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908841910661, language=CN, stringName=彭思芊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651909110346122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651909190037900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909110346122, language=EN, stringName=Yan ZHENG, firstName=Yan, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651909261341069, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909110346122, language=CN, stringName=郑岩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908497977723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=2., ext=[AuthorCompanyExt(id=1326651908510560636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326651908523143549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326651909353615759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651909613662609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909353615759, language=EN, stringName=Qihang YU, firstName=Qihang, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911358493074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909353615759, language=CN, stringName=于启航, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908497977723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=2., ext=[AuthorCompanyExt(id=1326651908510560636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326651908523143549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326651911417213332, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651911488516502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911417213332, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911564013975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911417213332, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651911635317145, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651911710814619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911635317145, language=EN, stringName=Junlong Wang, firstName=Junlong, middleName=null, lastName=Wang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911773729180, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911635317145, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])])], keywords=[Keyword(id=1326651911895363997, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=EN, orderNo=1, keyword=idiopathic pulmonary fibrosis), Keyword(id=1326651911954084254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=EN, orderNo=2, keyword=progressive pulmonary fibrosis), Keyword(id=1326651912033776031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=EN, orderNo=3, keyword=pulmonary fibrosis), Keyword(id=1326651912117662112, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=EN, orderNo=4, keyword=antifibrotic therapy), Keyword(id=1326651912188965281, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=EN, orderNo=5, keyword=artificial intelligence), Keyword(id=1326651912247685538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=CN, orderNo=1, keyword=特发性肺纤维化), Keyword(id=1326651912314794403, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=CN, orderNo=2, keyword=进展性肺纤维化), Keyword(id=1326651912377708964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=CN, orderNo=3, keyword=肺纤维化), Keyword(id=1326651912449012133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=CN, orderNo=4, keyword=抗纤维化治疗), Keyword(id=1326651912549675430, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, language=CN, orderNo=5, keyword=人工智能)], refs=[Reference(id=1326651912667115943, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=CARROLL MB, FELS ELLIOTT DR, KANNE JP, et al.Update on pulmonary fibrosis[J]. Adv Clin Radiol, 2024,6(1): 253-267., articleTitle=null, refAbstract=null), Reference(id=1326651912738419112, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU GY, BUDINGER GRS, DEMATTE JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis[J]. Br Med J, 2022, 377: e066354., articleTitle=null, refAbstract=null), Reference(id=1326651912792945065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=郑小兵, 金琳羚, 黄文, 等. 进展性纤维化性间质性肺疾病与抗纤维化治疗[J]. 中华结核和呼吸杂志, 2021, 44(6):569-573., articleTitle=null, refAbstract=null), Reference(id=1326651912906191274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=COPELAND CR, LANCASTER LH. Management of progressive fibrosing interstitial lung diseases(PF-ILD)[J].Front Med(Lausanne), 2021, 8: 743977., articleTitle=null, refAbstract=null), Reference(id=1326651912960717227, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=RAGHU G, REMY-JARDIN M, RICHELDI L, et al.Idiopathic Pulmonary Fibrosis(an Update) and progressive pulmonary fibrosis in adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2022, 205(9): e18-e47., articleTitle=null, refAbstract=null), Reference(id=1326651913044603308, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=毛萌萌, 郭炳鹏, 韩茜. 《成人特发性肺纤维化(更新)和进展性肺纤维化:ATS/ERS/JRS/ALAT临床实践指南(2022版)》解读(一):进展性肺纤维化识别与治疗[J]. 国际呼吸杂志, 2023, 43(11): 1245-1250., articleTitle=null, refAbstract=null), Reference(id=1326651913136877997, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=KONDOH Y, ITO T, SAITO K, et al. Progressive pulmonary fibrosis(PPF): Estimation of incidence and treatment rates in Japan using a claims database[J]. Respir Investig, 2024,62(4): 702-709., articleTitle=null, refAbstract=null), Reference(id=1326651913220764078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=WIJSENBEEK M, KREUTER M, OLSON A, et al.Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management[J]. Curr Med Res Opin, 2019, 35(11): 2015-2024., articleTitle=null, refAbstract=null), Reference(id=1326651913308844463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=GEORGE PM, SPAGNOLO P, KREUTER M, et al.Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities[J]. Lancet Respir Med, 2020, 8(9): 925-934., articleTitle=null, refAbstract=null), Reference(id=1326651913401119152, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=HAMBLY N, FAROOQI MM, DVORKIN-GHEVA A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry[J]. Eur Respir J, 2022, 60(4): 2102571., articleTitle=null, refAbstract=null), Reference(id=1326651913514365361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=NAQVI M, HANNAH J, LAWRENCE A, et al. Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances[J]. Expert Rev Respir Med, 2024, 18(6): 397-407., articleTitle=null, refAbstract=null), Reference(id=1326651913682137522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=HILBERG O, HOFFMANN-VOLD AM, SMITH V, et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries[J].ERJ Open Res, 2022, 8(1): 00597-2021., articleTitle=null, refAbstract=null), Reference(id=1326651913757634995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=王苑颖, 叶俏. 进展性纤维化性间质性肺疾病概况[J]. 中华结核和呼吸杂志, 2021, 44(6): 562-565., articleTitle=null, refAbstract=null), Reference(id=1326651913824743860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=WONG AW, RYERSON CJ, GULER SA. Progression of fibrosing interstitial lung disease[J]. Respir Res, 2020,21(1): 32., articleTitle=null, refAbstract=null), Reference(id=1326651913887658421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=李怡华, 叶俏. 特发性肺纤维化治疗药物临床试验进展[J].中华结核和呼吸杂志, 2020, 43(3): 256-262., articleTitle=null, refAbstract=null), Reference(id=1326651913954767286, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=LIBRA A, SCIACCA E, MUSCATO G, et al. Highlights on future treatments of IPF: clues and pitfalls[J]. Int J Mol Sci,2024, 25(15): 8392., articleTitle=null, refAbstract=null), Reference(id=1326651914021876151, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=CHONG WH, AGRAWAL D, TAN ZY, et al. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD[J]. Heart Lung, 2024, 68: 242-253., articleTitle=null, refAbstract=null), Reference(id=1326651914093179320, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=LAMB YN. Nintedanib: A review in fibrotic interstitial lung diseases[J]. Drugs, 2021, 81(5): 575-586., articleTitle=null, refAbstract=null), Reference(id=1326651915900924345, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=AMATI F, STAINER A, POLELLI V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review[J].Int J Mol Sci, 2023, 24(9): 7849., articleTitle=null, refAbstract=null), Reference(id=1326651916022559162, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=MAHER TM, ASSASSI S, AZUMA A, et al. Design of a phase Ⅲ, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis(FIBRONEER-ILD)[J]. Br Med J Open Resp Res,2023, 10(1): e001580., articleTitle=null, refAbstract=null), Reference(id=1326651916152582587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=RICHELDI L, AZUMA A, COTTIN V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis[J]. N Engl J Med, 2022, 386(23): 2178-2187., articleTitle=null, refAbstract=null), Reference(id=1326651916324549052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=CORTE TJ, LANCASTER L, SWIGRIS JJ, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1(LPA1) antagonist, in patients with idiopathic pulmonary fibrosis(IPF) or progressive fibrotic interstitial lung disease(PF-ILD)[J]. Br Med J Open Resp Res, 2021, 8(1):e001026., articleTitle=null, refAbstract=null), Reference(id=1326651916462961085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=CORTE TJ, BEHR J, COTTIN V, et al. Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial[J]. Am J Respir Crit Care Med, 2025, 211(2): 230-238., articleTitle=null, refAbstract=null), Reference(id=1326651916601373118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=MAHER TM, GOLDIN JG, HOOD J, et al. Taladegib for the treatment of idiopathic pulmonary fibrosis(ENV-IPF-101):a multicentre, randomised, double-blind, placebo-controlled,phase 2a trial[J]. Lancet Respir Med, 2025, 13(11): 1001-1010., articleTitle=null, refAbstract=null), Reference(id=1326651916731396543, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=REN F, ALIPER A, CHEN J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models[J].Nat Biotechnol, 2025, 43(1): 63-75., articleTitle=null, refAbstract=null), Reference(id=1326651916827865536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=CHENG W, ZENG Y, WANG D. Stem cell-based therapy for pulmonary fibrosis[J]. Stem Cell Res Ther, 2022, 13(1):492., articleTitle=null, refAbstract=null), Reference(id=1326651916987249089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=AVERYANOV A, KOROLEVA I, KONOPLYANNIKOV M,et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline[J]. Stem Cells Transl Med, 2020, 9(1): 6-16., articleTitle=null, refAbstract=null), Reference(id=1326651917113078210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=RUIGROK MJR, FRIJLINK HW, MELGERT BN, et al.Gene therapy strategies for idiopathic pulmonary fibrosis:recent advances, current challenges, and future directions[J].Mol Ther Methods Clin Dev, 2021, 20: 483-496., articleTitle=null, refAbstract=null), Reference(id=1326651917276656067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG Y, TANG Y, ZHAO XM, et al. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy[J]. Acta Biomater, 2022, 153: 481-493., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)]), AuthorCompany(id=1326651908497977723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=2., ext=[AuthorCompanyExt(id=1326651908510560636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326651908523143549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.11.014, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.11.014, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.11.014, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.11.014, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1762704000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
进展性肺纤维化抗纤维化治疗的临床研究新进展
曾艳艳 1 , 彭思芊 1 , 郑岩 2 , 于启航 2 , 倪娜 1, * , 王俊龙 1, *
世界临床药物 | 综述评论 2025,46(11): 1181-1187
收起
收藏切换
世界临床药物 |综述评论 2025 , 46 (11) : 1181 -1187
进展性肺纤维化抗纤维化治疗的临床研究新进展
全屏
[Author(id=1326651908598641023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651908678332801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908598641023, language=EN, stringName=Yanyan ZENG, firstName=Yanyan, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651908762218882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908598641023, language=CN, stringName=曾艳艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

"}, bioImg=null, bioContent=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651908841910661, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651908955156871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908841910661, language=EN, stringName=Siqian PENG, firstName=Siqian, middleName=null, lastName=PENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651909039042952, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651908841910661, language=CN, stringName=彭思芊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651909110346122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651909190037900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909110346122, language=EN, stringName=Yan ZHENG, firstName=Yan, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651909261341069, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909110346122, language=CN, stringName=郑岩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908497977723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=2., ext=[AuthorCompanyExt(id=1326651908510560636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326651908523143549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326651909353615759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651909613662609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909353615759, language=EN, stringName=Qihang YU, firstName=Qihang, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911358493074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651909353615759, language=CN, stringName=于启航, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908497977723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=2., ext=[AuthorCompanyExt(id=1326651908510560636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326651908523143549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908497977723, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326651911417213332, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651911488516502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911417213332, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911564013975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911417213332, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326651911635317145, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651911710814619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911635317145, language=EN, stringName=Junlong Wang, firstName=Junlong, middleName=null, lastName=Wang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651911773729180, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, authorId=1326651911635317145, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651908414091640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, xref=1., ext=[AuthorCompanyExt(id=1326651908422480249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326651908430868858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651907667505525, companyId=1326651908414091640, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])])]
曾艳艳1, 彭思芊1, 郑岩2, 于启航2, 倪娜1, *, 王俊龙1, *
作者信息
  • 1.中国医药工业研究总院临床研究中心,上海 200437
  • 2.上海益临思医药开发有限公司,上海 200437
通讯作者:
倪娜,副研究员,研究方向:创新药物的临床研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
作者简介:

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis
Yanyan ZENG1, Siqian PENG1, Yan ZHENG2, Qihang YU2, Na NI1, *, Junlong Wang1, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
出版时间: 2025-11-10 doi: 10.13683/j.wph.2025.11.014
文章导航
收藏切换

2022年美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布的临床实践指南首次提出进展性肺纤维化(progressive pulmonary fibrosis,PPF)这一术语,用于统称除特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)外的其他类型间质性肺疾病进行性纤维化表型。此类疾病即使经过规范化治疗,仍可能呈现与IPF相似的临床病程特征及纤维化核心机制。目前,美国食品药品监督管理局批准的2种抗纤维化药物尼达尼布及吡非尼酮,仅能减缓IPF患者的肺功能下降,无法逆转纤维化。由于PPF患者群体异质性强、入组标准复杂,针对PPF的临床试验常因招募困难而终止。当前药物研发策略多选择以IPF为初始适应证,待验证有效性后逐步拓展至其他肺纤维化疾病。在研发管线中,多数候选药物尚处于临床早期阶段,仅少数进入Ⅱ/Ⅲ期临床试验并同步探索PPF适应证。值得注意的是,2024年全球首款基于纯人工智能设计的抗纤维化药物INS018-055已成功推进至Ⅱ期临床试验,标志着人工智能技术在药物开发中的突破性应用。该文系统解析PPF的概念框架,涵盖其定义、疾病谱系、流行病学特征及分子机制,并基于抗纤维化治疗视角综述最新临床研究进展,旨在为新型靶点发现及转化研究提供理论依据。

特发性肺纤维化  /  进展性肺纤维化  /  肺纤维化  /  抗纤维化治疗  /  人工智能

In 2022, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association jointly released a clinical practice guideline that introduced the term progressive pulmonary fibrosis (PPF) to collectively refer to the progressive fibrotic phenotypes of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). These diseases may exhibit clinical course characteristics and core mechanisms of fibrosis similar to those of IPF, even after standardized treatment. Currently, the two anti-fibrotic drugs nintedanib and pirfenidone approved by the U.S. Food and Drug Administration, can only slow the decline in lung function in patients with IPF, but cannot reverse fibrosis. Due to the significant heterogeneity of PPF patient population and complex enrollment criteria, clinical trials targeting PPF often terminate due to recruitment challenges. Consequently, current drug development strategies primarily select IPF as the initial indication and then gradually expand to other fibrotic lung diseases after confirming effectiveness. In the research and development pipeline, most candidate drugs remain in the early stages of clinical development, with only a few advancing to phase Ⅱ/Ⅲ clinical studies and simultaneously exploring the PPF indication. Notably, in 2024, the world's first anti-fibrotic drug designed entirely using artificial intelligence (AI), INS018-055, successfully progressed to Phase Ⅱ clinical trials, marking a significant breakthrough application of AI technology in drug development. This article systematically dissected the conceptual framework of PPF, covering its definition, disease spectrum, epidemiological characteristics, and molecular mechanisms, while reviewed the latest clinical research advancements from the perspective of anti-fibrotic treatment, aiming to provide a theoretical foundation for the discovery of new targets and translational research.

idiopathic pulmonary fibrosis  /  progressive pulmonary fibrosis  /  pulmonary fibrosis  /  antifibrotic therapy  /  artificial intelligence
曾艳艳, 彭思芊, 郑岩, 于启航, 倪娜, 王俊龙. 进展性肺纤维化抗纤维化治疗的临床研究新进展. 世界临床药物, 2025 , 46 (11) : 1181 -1187 . DOI: 10.13683/j.wph.2025.11.014
Yanyan ZENG, Siqian PENG, Yan ZHENG, Qihang YU, Na NI, Junlong Wang. Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis[J]. World Clinical Drug, 2025 , 46 (11) : 1181 -1187 . DOI: 10.13683/j.wph.2025.11.014

参考文献 引证文献
排序方式:
[1]
CARROLL MB, FELS ELLIOTT DR, KANNE JP, et al.Update on pulmonary fibrosis[J]. Adv Clin Radiol, 2024,6(1): 253-267.
[2]
LIU GY, BUDINGER GRS, DEMATTE JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis[J]. Br Med J, 2022, 377: e066354.
[3]
郑小兵, 金琳羚, 黄文, 等. 进展性纤维化性间质性肺疾病与抗纤维化治疗[J]. 中华结核和呼吸杂志, 2021, 44(6):569-573.
[4]
COPELAND CR, LANCASTER LH. Management of progressive fibrosing interstitial lung diseases(PF-ILD)[J].Front Med(Lausanne), 2021, 8: 743977.
[5]
RAGHU G, REMY-JARDIN M, RICHELDI L, et al.Idiopathic Pulmonary Fibrosis(an Update) and progressive pulmonary fibrosis in adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
[6]
毛萌萌, 郭炳鹏, 韩茜. 《成人特发性肺纤维化(更新)和进展性肺纤维化:ATS/ERS/JRS/ALAT临床实践指南(2022版)》解读(一):进展性肺纤维化识别与治疗[J]. 国际呼吸杂志, 2023, 43(11): 1245-1250.
[7]
KONDOH Y, ITO T, SAITO K, et al. Progressive pulmonary fibrosis(PPF): Estimation of incidence and treatment rates in Japan using a claims database[J]. Respir Investig, 2024,62(4): 702-709.
[8]
WIJSENBEEK M, KREUTER M, OLSON A, et al.Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management[J]. Curr Med Res Opin, 2019, 35(11): 2015-2024.
[9]
GEORGE PM, SPAGNOLO P, KREUTER M, et al.Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities[J]. Lancet Respir Med, 2020, 8(9): 925-934.
[10]
HAMBLY N, FAROOQI MM, DVORKIN-GHEVA A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry[J]. Eur Respir J, 2022, 60(4): 2102571.
[11]
NAQVI M, HANNAH J, LAWRENCE A, et al. Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances[J]. Expert Rev Respir Med, 2024, 18(6): 397-407.
[12]
HILBERG O, HOFFMANN-VOLD AM, SMITH V, et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries[J].ERJ Open Res, 2022, 8(1): 00597-2021.
[13]
王苑颖, 叶俏. 进展性纤维化性间质性肺疾病概况[J]. 中华结核和呼吸杂志, 2021, 44(6): 562-565.
[14]
WONG AW, RYERSON CJ, GULER SA. Progression of fibrosing interstitial lung disease[J]. Respir Res, 2020,21(1): 32.
[15]
李怡华, 叶俏. 特发性肺纤维化治疗药物临床试验进展[J].中华结核和呼吸杂志, 2020, 43(3): 256-262.
[16]
LIBRA A, SCIACCA E, MUSCATO G, et al. Highlights on future treatments of IPF: clues and pitfalls[J]. Int J Mol Sci,2024, 25(15): 8392.
[17]
CHONG WH, AGRAWAL D, TAN ZY, et al. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD[J]. Heart Lung, 2024, 68: 242-253.
[18]
LAMB YN. Nintedanib: A review in fibrotic interstitial lung diseases[J]. Drugs, 2021, 81(5): 575-586.
[19]
AMATI F, STAINER A, POLELLI V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review[J].Int J Mol Sci, 2023, 24(9): 7849.
[20]
MAHER TM, ASSASSI S, AZUMA A, et al. Design of a phase Ⅲ, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis(FIBRONEER-ILD)[J]. Br Med J Open Resp Res,2023, 10(1): e001580.
[21]
RICHELDI L, AZUMA A, COTTIN V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis[J]. N Engl J Med, 2022, 386(23): 2178-2187.
[22]
CORTE TJ, LANCASTER L, SWIGRIS JJ, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1(LPA1) antagonist, in patients with idiopathic pulmonary fibrosis(IPF) or progressive fibrotic interstitial lung disease(PF-ILD)[J]. Br Med J Open Resp Res, 2021, 8(1):e001026.
[23]
CORTE TJ, BEHR J, COTTIN V, et al. Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial[J]. Am J Respir Crit Care Med, 2025, 211(2): 230-238.
[24]
MAHER TM, GOLDIN JG, HOOD J, et al. Taladegib for the treatment of idiopathic pulmonary fibrosis(ENV-IPF-101):a multicentre, randomised, double-blind, placebo-controlled,phase 2a trial[J]. Lancet Respir Med, 2025, 13(11): 1001-1010.
[25]
REN F, ALIPER A, CHEN J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models[J].Nat Biotechnol, 2025, 43(1): 63-75.
[26]
CHENG W, ZENG Y, WANG D. Stem cell-based therapy for pulmonary fibrosis[J]. Stem Cell Res Ther, 2022, 13(1):492.
[27]
AVERYANOV A, KOROLEVA I, KONOPLYANNIKOV M,et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline[J]. Stem Cells Transl Med, 2020, 9(1): 6-16.
[28]
RUIGROK MJR, FRIJLINK HW, MELGERT BN, et al.Gene therapy strategies for idiopathic pulmonary fibrosis:recent advances, current challenges, and future directions[J].Mol Ther Methods Clin Dev, 2021, 20: 483-496.
[29]
WANG Y, TANG Y, ZHAO XM, et al. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy[J]. Acta Biomater, 2022, 153: 481-493.
2025年第46卷第11期
53
13
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.11.014
  • 接收时间:2025-03-24
  • 首发时间:2026-11-09
  • 出版时间:2025-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-03-24
基金
作者信息
    1.中国医药工业研究总院临床研究中心,上海 200437
    2.上海益临思医药开发有限公司,上海 200437

通讯作者:

倪娜,副研究员,研究方向:创新药物的临床研究。
王俊龙,副研究员,研究方向:创新药物的临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.11.014
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏